Mean Arterial Pressure After Out-of-hospital Cardiac Arrest

Status Not yet recruiting

Clinical Trial Summary

Out-of-hospital cardiac arrest is a public health problem for which overall survival is below 10%. Post-cardiac arrest syndrome is the principal cause of death in intensive care units (ICU), due to refractory shock or brain injuries secondary to anoxia. Brain anoxia is responsible for severe neurological sequelae that may be aggravated by cerebral hypoperfusion during the first few hours after the return of spontaneous circulation. Current recommendations are to ensure that arterial blood pressure is sufficient for the perfusion of organs, but no minimum threshold mean arterial pressure (MAP) has been defined. In practice, most teams target a MAP of at least 65 mmHg. Several observational studies have shown a correlation between MAP and neurological prognosis, patients with a higher initial MAP having a better outcome. Recent pilot studies have demonstrated the feasibility of increasing the target MAP after cardiac arrest, but conflicting results have been obtained concerning patient prognosis. These findings may be explained by changes to the autoregulation of the brain after cardiac arrest, with a shift of the curve towards the right, or its abolition. Cerebral blood flow is dependent on MAP, and a target MAP of 65 mmHg for these patients may result in insufficient brain perfusion. Conversely, a too high MAP might cause brain lesions due to vasogenic edema, hemorrhagic complications or excess perfusion in conditions of diminished brain metabolism. An interventional study is required to evaluate the effect of increasing MAP on neurofunctional outcome after cardiac arrest. Given the data available for brain autoregulation, the correlation between MAP and prognosis, and the risks theoretically associated with a higher MAP, investigator plans to compare a standard threshold of MAP (≥ 65 mmHg) with a high threshold of MAP (≥ 90 mmHg). Investigator hypothesizes that a high MAP within the first 24 hours after cardiac arrest will improve neurofunctional outcome.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05486884
Study type	Interventional
Source	Centre Hospitalier le Mans
Contact	Christelle JADEAU
Phone	+33244710781
Email	cjadeau@ch-lemans.fr
Status	Not yet recruiting
Phase	N/A
Start date	July 1, 2023
Completion date	April 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06048068` - Removing Surrogates' Uncertainty to Reduce Fear and Anxiety After Cardiac Events	N/A
Recruiting	`NCT05558228` - Accuracy of Doppler Ultrasound Versus Manual Palpation of Pulse in Cardiac Arrest
Completed	`NCT03685383` - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation	N/A
Completed	`NCT04584645` - A Digital Flu Intervention for People With Cardiovascular Conditions	N/A
Completed	`NCT04619498` - Effectiveness of an Interactive Cognitive Support Tablet App to Improve the Management of Pediatric Cardiac Arrest	N/A
Not yet recruiting	`NCT05649891` - Checklists Resuscitation Emergency Department	N/A
Withdrawn	`NCT02352350` - Lactate in Cardiac Arrest	N/A
Completed	`NCT03024021` - Cerebral Oxymetry and Neurological Outcome in Therapeutic Hypothermia
Completed	`NCT02247947` - Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome
Completed	`NCT02275234` - Care After Resuscitation
Completed	`NCT01936597` - Prospective Study of 3 Phone Assistance Strategies to Achieve a Continuous Cardiac Massage	N/A
Completed	`NCT01972087` - Simulation Training to Improve 911 Dispatcher Identification of Cardiac Arrest	N/A
Completed	`NCT01944605` - Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest	N/A
Active, not recruiting	`NCT01239420` - Norwegian Cardio-Respiratory Arrest Study
Completed	`NCT00878644` - Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial	Phase 3
Completed	`NCT01191736` - Ultra-Brief Versus Brief Hands Only CPR Video Training With and Without Psychomotor Skill Practice	N/A
Completed	`NCT00880087` - Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial	N/A
Completed	`NCT00729794` - Vasopressin, Epinephrine, and Steroids for Cardiac Arrest	Phase 3
Recruiting	`NCT00441753` - Cerebral Bloodflow and Carbondioxide Reactivity During Mild Therapeutic Hypothermia in Patients After Cardiac Arrest	N/A
Completed	`NCT00347477` - Fluid Shifts in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Mean Arterial Pressure After Out-of-hospital Cardiac Arrest — METAPHORE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms